MAX-ACT

K983649 · Array Medical, Inc. · JBP · Dec 11, 1998 · Hematology

Device Facts

• Record ID: K983649
• Device Name: MAX-ACT
• Applicant: Array Medical, Inc.
• Product Code: JBP · Hematology
• Decision Date: Dec 11, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 864.7140
• Device Class: Class 2
• Attributes: Pediatric

Intended Use

The MAX-ACT Activated Clotting Time test tubes are intended for use in the measurement of the activated clotting time test (ACT) on Actalyke Models A1, A1P, A2, A2P, and Hemochron® Models 400, 401, 800, 801 and 8000.

Device Story

MAX-ACT test tubes contain a cocktail of particulate activators (celite, kaolin, glass particles) to initiate blood clotting. Used with Actalyke or Hemochron instruments to measure activated clotting time (ACT) in whole blood samples. Operated by clinicians in clinical settings (bypass, catheterization labs) to monitor heparinization levels. Instrument detects clotting time; output used by physicians to adjust heparin dosage during procedures. Benefits include standardized heparin monitoring across various patient populations, including those receiving antifibrinolytic therapy.

Clinical Evidence

Clinical studies included 330 paired blood samples from four groups: adult bypass (n=239), aprotinin-treated bypass (n=28), pediatric bypass (n=41), and cardiac catheterization (n=22). MAX-ACT results were compared against reference celite-based (C-ACT/FTCA510) or kaolin-based (ACTII/K-ACT/FTKACT) tests. Correlation coefficients (r2) ranged from 0.82 to 0.89 across groups. In-vitro testing (n=72) showed a positive correlation (r=0.97, p=.0001) with reference C-ACT tubes.

Technological Characteristics

Test tubes containing particulate activator cocktail (celite, kaolin, glass particles). Compatible with Actalyke and Hemochron instrument platforms. Measures activated clotting time via mechanical or optical sensing (instrument-dependent).

Indications for Use

Indicated for the measurement of activated clotting time (ACT) in patients undergoing procedures requiring heparinization, including adult and pediatric cardiopulmonary bypass and cardiac catheterization.

Regulatory Classification

Identification

An activated whole blood clotting time tests is a device, used to monitor heparin therapy for the treatment of venous thrombosis or pulmonary embolism by measuring the coagulation time of whole blood.

Predicate Devices

• Array Medical Actalyke C-ACT test tube (K964609)

Reference Devices

• HEMOCHRON CA510
• Hemochron FTKACT
• ACTII/K-ACT/FTKACT
• FTCA510

Submission Summary (Full Text)

{0}------------------------------------------------

DEC 1 1 1998

K983649

### 510(k) Summary of Safety and Effectiveness Information MAX-ACT Activated Clotting Time Test Tube

Array Medical, Inc. One Harvard Way, Suite 5 Hillsborough Campus Somerville, NJ 08876 908-707-8872

Michael F. Corsello, 908-707-8872 Contact:

October 12, 1998 Date:

Device Names:

Trade Names: MAX-ACT

Activated clotting time test Common Name:

Classification Name: Activated whole blood clotting time tests

Legally Marketed Device:

Array Medical Actalyke C-ACT test tube, K964609.

Device Description:

The MAX-ACT Activated Clotting Time test tubes utilize a "cocktail" of particulate activators (including celite, kaolin, and glass particles) and is intended for use in the measurement of the activated clotting time test (ACT) on Actalyke Models A1, A1P, A2, A2P, and Hemochron® Models 400, 401, 800, 801 and 8000.

Intended Use:

The MAX-ACT Activated Clotting Time test tubes are intended for use in the measurement of the activated clotting time test (ACT) on Actalyke Models A1, A1P, A2, A2P, and Hemochron® Models 400, 401, 800, 801 and 8000.

{1}------------------------------------------------

Performance Data:

Substantial equivalence of the MAX-ACT ACT test tubes to the Array Medical Actalyke C-ACT is supported by an in-house study.

Whole blood was obtained from normal donors and heparinized in vitro up to 10.0 units of heparin/ml. Currently, the most common method for heparin monitoring in these heparinization ranges are the celite and kaolin based ACT tests (C-ACT (celite) and K-ACT (kaolin) (0.0-5.0 units/ml - 600 seconds) and HEMOCHRON CA510 (celite) (up to 600 seconds). Hemochron FTKACT (kaolin) (up to 600 seconds). The correlation of the MAX-ACT Activated Clotting Time test tube and various combinations of Actalyke and Hemochron instruments and ACT tubes were determined.

In-vitro heparin sensitivity curves were generated from three normal, healthy volunteers. Samples (n=72) were generated by adding increasing amounts of heparin to aliquots of normal donor blood. MAX-ACT Activated Clotting Time Tests were performed.

A positive correlation between the MAX-ACT and the C-ACT/FTCA510 was demonstrated when paired testing was performed. The MAX-ACT demonstrated a positive correlation with the C-ACT tubes (r=0.97, p=.0001, n=72) (Figure E1). The data is shown in Table E1.

Studies were also conducted clinically at numerous institutions. A total of 330 paired blood samples were collected from patients (including adult bypass, pediatric bypass, and cardiac catheterization) before, during, and following heparinization. The patients were divided into four discrete groups. These groups consisted of:

Study Group 1. Bypass Patients: Results obtained using a reference celite-based ACT test (C-ACT/FTCA510) were compared to those obtained using MAX-ACT test tubes. A total of 239 patient samples were collected from bypass patients (n=30) before, during, and following heparinization during cardiopulmonary bypass. The data vielded a correlation coefficient of r2 =0.82 (Figure E2) and r2 = 0.87 (Figure E3) when samples from the reference group were omitted which were outside the published linear range for the reference tube. The data is shown in Table E2.

Study Group 2. Aprotinin Bypass Patients: Results obtained using a reference kaolin-based ACT test (ACTII/K-ACT/FTKACT) were compared to those obtained using MAX-ACT test tubes. A total of 28 patient samples were collected from bypass patients receiving antifibrinolytic therapy (aprotinin) (n=6) before, during, and following heparinization during cardiopulmonary bypass. The data yielded a correlation coefficient of r2 =0.89 (Figure E4). The data is shown in Table E3.

{2}------------------------------------------------

Study Group 3. Pediatric Bypass: Results obtained using a reference celitebased ACT test (FTCA510) were compared to those obtained using MAX-ACT test tubes. A total of 41 patient samples were collected from pediatric bypass patients (n=5) before, during, and following heparinization during cardiopulmonary bypass. The data yielded a correlation coefficient of r2=0.86 (Figure E5). The data is shown in Table E4.

Study Group 4. Catheterization Patients: Results obtained using a reference celite-based ACT test (FTCA510) were compared to those obtained using MAX-ACT test tubes. A total of 22 patient samples were collected from cardiac catheterization patients (n=10) before, during, and following heparinization during the procedure (diagnostic and interventional). The data vielded a correlation coefficient of 2 =0.88 (Figure E6). The data is shown in Table E5.

{3}------------------------------------------------

#### DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three stylized human profiles facing to the right.

DEC 1 1 1998

Mr. Michael F. Corsello Array Medical, Inc. One Harvard Way, Suite 5 Hillsborough Campus Somerville, New Jersey 08876

Re : K983649 Trade Name: MAX-ACT Regulatory Class: II Product Code: JBP Dated: October 14, 1998 Received: October 16, 1998

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existinq major requlations affectinq your device can be found in the Code of Federal Requlations, Title 21, Parts 800 A substantially equivalent determination assumes compliance to 895. with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

{4}------------------------------------------------

#### Page 2

This letter will allow you to beqin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diaqnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbrandinq by reference to premarket notification"(21 CFR 807.97). Other qeneral information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation . Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

## Statement of Indications For Use

510(k) Number:

K983649

Device Namo:

# MAX-ACT™ Activated Clotting Time Tubes

"Indications For Use" -

The MAX-ACT Activated Clotting Time test tubes are I lie MAX-AOT - Floridae - Frences of the activated clotting time Intended for the measure Models A1, A1P, A2, A2P, and on (ACT) test on Piels 400,401,800,801, and 8000.

Peter R. Mafini

(Please do not write below this point)

Concurrence of CDRH, Office of Device Evaluation (ODE)

ﮯ Prescription Use (per 21 CFR 801.109)

Or

Over-The-Counter Use